SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

MYnd Analytics, Inc. – ‘425’ on 5/23/19 re: MYnd Analytics, Inc. – ‘EX-5.1’

On:  Thursday, 5/23/19, at 8:36am ET   ·   Accession #:  1615774-19-8286   ·   File #:  1-35527

Previous ‘425’:  ‘425’ on 5/13/19   ·   Next & Latest:  ‘425’ on 7/9/19

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/23/19  MYnd Analytics, Inc.              425                    5:267K MYnd Analytics, Inc.              S2 Filings LLC/FA

Business-Combination Transaction Communication   —   Rule 425
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 425         Business-Combination Transaction Communication      HTML     24K 
 2: EX-1.1      Underwriting Agreement                              HTML     14K 
 3: EX-5.1      Opinion re: Legality                                HTML     11K 
 4: EX-10.1     Material Contract                                   HTML    123K 
 5: EX-99.1     Miscellaneous Exhibit                               HTML     14K 


‘EX-5.1’   —   Opinion re: Legality


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 5.1

 

   

Dentons US LLP
1221 Avenue of the Americas
New York, NY 10020-1089
United States

 

大成 Salans FMC SNR Denton McKenna Long

dentons.com

 

May 23, 2019

 

MYnd Analytics, Inc.

26522 La Alameda, Suite 290
Mission Viejo, California 92691

 

Re: Sale of securities registered pursuant to Registration Statement on Form S-3 (File No. 333-223203)

 

Ladies and Gentlemen:

 

We have acted as counsel to MYnd Analytics, Inc., a Delaware corporation (the “Company”), in connection with a registration statement on Form S-3, File No. 333-223203 (the “Registration Statement”), heretofore filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”) and the prospectus supplement to be filed pursuant to Rule 424(b) under the Act, dated as of May 22, 2019 (the “Prospectus Supplement”), under which the Company offered 2,776,491 shares of the Company’s common stock, $0.001 par value per share (the “Shares”). The Shares are being sold pursuant to an securities purchase agreement dated May 22, 2019, by and between the Company and certain investors (the “Purchase Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreements.

 

This opinion is being delivered to you pursuant to Item 601(b)(5) of Regulation S-K under the Act at the request of the Company.

 

In connection with rendering this opinion, we have examined originals, certified copies or copies otherwise identified as being true copies of the following: (i) the Company’s Certificate of Incorporation, (ii) the Company’s By-Laws, (iii) the Registration Statement, including the prospectus (the “Base Prospectus”) contained therein, (iv) the Prospectus Supplement (such prospectus and the Base Prospectus are collectively referred to herein as the “Prospectus”), (v) corporate proceedings of the Company relating to the Shares, and (vi) such other instruments and documents as we have deemed relevant under the circumstances.

 

We have assumed the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity to originals of all copies of documents examined by us.

 

Based upon the foregoing, and in reliance thereon, and subject to the qualifications, limitations and exceptions stated herein, we are of the opinion having due regard for such legal considerations as we deemed relevant that:

 

1. The Shares, have been duly authorized and, when, sold and delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Prospectus, will be validly issued, fully paid and nonassessable.

 

 C: 

 

 

 

(Graphic)

MYnd Analytics, Inc.

May 23, 2019

Page 2

 

Salans FMC SNR Denton

dentons.com                       

 

Our opinions are subject to the effect of Federal and state bankruptcy, insolvency, reorganization, arrangement, moratorium, fraudulent conveyance and other laws relating to or affecting the rights of secured or unsecured creditors generally (or affecting the rights of only creditors of specific types of debtors), with respect to which we express no opinion.

 

Our opinions are subject to limitations imposed by general principles of equity or public policy upon the enforceability of any of the remedies or covenants, including, without limitation, concepts of materiality, good faith and fair dealing and upon the availability of injunctive relief or other equitable remedies, and the application of principles of equity (regardless of whether enforcement is considered in proceedings at law or in equity).

 

We express no opinion as to the laws of any jurisdiction other than Delaware corporate law and the federal laws of the United States of America.

 

We hereby consent to the inclusion of this opinion as an exhibit to a Current Report on Form 8-K and to the references to our firm under the caption “Legal Matters” in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

 

  Very truly yours,
   
  /s/ Dentons US LLP

 

 C: 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘425’ Filing    Date    Other Filings
Filed on:5/23/198-K
5/22/198-K
 List all Filings 
Top
Filing Submission 0001615774-19-008286   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 2:05:20.1pm ET